Puma Biotechnology, Inc. PBYI NASDAQ

Puma Biotechnology, Inc. (PBYI) generated $41.8M in operating cash flow for fiscal year 2025. After capital expenditures of $71K, free cash flow was $41.73M.

Free cash flow margin was 18.3% of revenue. Cash conversion ratio was 1.34x, indicating earnings are backed by cash.

Criteria supported by this page:

• HEALTH (83/100, Pass) — demonstrate the company can comfortably service its debt
• MOAT (54/100, Partial) — cash flow generation is present but not at levels indicating a wide moat
• INCOME (55/100) — Cash conversion ratio was 1.34x confirms earnings are backed by real cash flow

Overall SharesGrow Score: 69/100 with 4/7 criteria passed.